1. Mike Chappell School of Engineering
Warwick Engineering in Biomedicine - WEB

2. Biomedical Systems Modelling (Mike Chappell)
Mathematical/metabolic systems modelling of biomedical, biological and pharmacokinetic (PK) processes
Mechanistic (knowledge-based) modelling – predictive capability for screening, diagnosis and therapy
Quantitative and Systems Pharmacology
Collaborators
AstraZeneca (UK & Sweden), The Binding Site(TBS), QE B’ham, LSTM, UHCW, School of Med. Cardiff, Fraunhofer Chalmers Centre, Uppsala Univ., Warwick CDTs and Gambro/Baxter
Expertise in structural identifiability &
indistinguishability analyses
Surface plasmon resonance (SPR) used to determine affinities in incompatible renal transplants – knowledge of identifiability essential

3. Compartmental Modelling – clearance of free light chains (withTBS)
4 PhD students over last 10 years
Myeloma is a cancer of plasma cells
excess monoclonal FLCs
renal damage
Combine chemotherapy with dialysis to protect kidney? (EuLITE & Patent)
REF Impact Case Study
1: 100% kill
4: +HD (4hrs 3x/wk)
2: 10%/day kill
5: +HD (8 hrs /day)
3: +PE (6 x 3.5l)
Bradwell. Serum Free Light Chain Analysis, 2010

4. Warwick/AstraZeneca (AZ) Collaborations
IMPACT (Innovative Modelling for Pharmacological Advances through Collaborative Training) in collaboration with AstraZeneca (Mölndal, Sweden & Alderley Park/Cambridge) and associate partners - EU, Marie Curie People ITN European Industrial Doctorate (EID) scheme(€1.467M)
“Structural Identifiability and Indistinguishability Analysis as Tools for Quantitative and Systems Toxicology” supporting the replacement, reduction and refinement (3Rs) of animal use. Funded by the NC3Rs/EPSRC (£245K)
Modelling the kinetics of BCRP/hepatic transporters and associated inhibitors – (MRC Capacity Building Studentship + AZ top-up)
Modelling and control of glucose-insulin dynamics (Type 2 diabetes) – (AZ funded PhD studentship)
Mechanistic modelling of in vitro transporter data to improve translational modelling of the transporter-mediated human pharmacokinetics and DDI predictions (BBSRC Case Award with AZ, began February 2015)

5. Quantitative and Systems Pharmacology (QSP)
Systems pharmacology - an emerging discipline, which connects systems biology (i.e. genomics, proteomics, and metabolomics) to quantitative pharmacology (i.e. mechanism-based PKPD modelling) to obtain fundamental insights in the interactions between drugs and diseases.
Recently, interest in this field has increased substantially. It is seen as a novel scientific approach to the design of (complex) therapeutic interventions to modify disease processes.
Now have an EPSRC funded national network QSP-UK in this area that also includes all of the major pharma companies based in the UK ans associated SMEs. Network workshops planned:
- Surrey (5th-7th September 2016)
- Warwick (September 2017)
- Reading (July 2018)
See: